Marzia Pendino (PhD Award) and Dr Husvinee Sundaramurthi (Post-doctoral Award)

Patients diagnosed with primary eye cancer or uveal melanoma (UM) have poor survival. Furthermore, approximately 50% will suffer from metastatic UM with a median overall survival of 4 to 15 months, with approximately 15% of patients making it to the one-year mark. Within Ireland, it is estimated that the incidence rate of UM per capita is 1.3 cases/100,000 yearly, higher than in the UK or USA.

Current treatment options are surgical removal of the eye and combined radiation therapy. Hence, there is an imperative need to identify novel drugs to treat uveal melanoma. Histone deacetylase 6 inhibitors (HDAC6i) have shown great promise as an anti-neoplastic agent and are currently under clinical trial investigations for other cancers. The goal of this study is to: 1) identify the capability of HDAC6i to prevent UM tumor growth and 2) understand how HDAC6i works to prevent UM tumor growth.  It is hoped that this study will lead to new therapies for UM.

Publications

Sundaramurthi H, García-Mulero S, Tonelotto V, Slater K, Marcone S, Piulats JM, Watson RW, Tobin DJ, Jensen LD, Kennedy BN. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. Cancers. 2022; 14(3):782. https://doi.org/10.3390/cancers14030782

Cancers | Free Full-Text | Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor (mdpi.com)

 

Back
Start Date
2020
Principal Investigator
Prof Breandán N Kennedy
Researcher
Dr Husvinee Sundaramuthi
Institution
UCD Conway Institute, University College Dublin
Grant funding
Irish Research Council Enterprise Partnership Scheme (Postdoctoral) with Breakthrough Cancer Research as partners
Linked Breakthrough Research Priorities
1, 2, 3, 4, 5

View More